Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07915947
PHASE1

LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study

Sponsor: Latigo Biotherapeutics

View on ClinicalTrials.gov

Summary

This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in combination with itraconazole, in healthy participants.

Official title: A Phase 1, Open-Label Study to Evaluate the Effect of Strong CYP3A Inhibition on the Pharmacokinetics of LTG-321 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2026-12-04

Completion Date

2026-12-30

Last Updated

2026-11-04

Healthy Volunteers

Yes

Interventions

DRUG

LTG-321

LTG-321 is a novel, orally bioavailable, small molecule NaV1.8 inhibitor being developed as a non-opioid analgesic product

DRUG

Itraconazole (200 mg)

Itraconazole is a known strong CYP3A inhibitor